Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
Study sponsor: Arcturus Therapeutics, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-12-28Actual
Enrollment · participants65Actual
Source updated2024-12-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.